Triple Agonist · Metabolic & Weight Loss Research · COA Verified
For research and laboratory use only. Not for human consumption. By purchasing, you confirm you are a qualified researcher.
For Research Purposes Only. Not approved for human consumption.
GLP3 is a synthetic triple hormone receptor agonist peptide — a first-in-class compound that simultaneously activates GLP-1, GIP, and glucagon receptors. In Phase 3 trials, GLP3 achieved unprecedented 24.2% mean weight loss at the 12mg dose over 48 weeks, with 91% of participants achieving ≥15% body weight reduction. It represents one of the most advanced metabolic peptides in clinical research, offering researchers a unique tool for studying triple-pathway metabolic regulation.
Q: What makes GLP3 unique?
A: It is the first triple agonist (GLP-1 + GIP + Glucagon) studied in Phase 3 trials. Most metabolic peptides target one receptor; GLP2 targets two. GLP3 targets all three simultaneously.
Q: What were the Phase 3 trial results?
A: 2,539 participants: 12mg dose achieved 24.2% mean weight loss; 8mg dose 22.8%; 91% achieved ≥15% reduction at highest dose. Published in NEJM 2023.
Q: How does the glucagon component work?
A: Low-level glucagon receptor activation may increase resting energy expenditure via thermogenesis and enhanced lipolysis — complementing the appetite-suppressing effects of GLP-1 and GIP.
Related Research: Complete Retatrutide Research Guide | 2026 Research Update | Weight Loss Mechanisms | GLP1 Research Peptide | GLP2 Research Peptide | Cagrilintide Research Peptide | What Is Retatrutide? | Are Research Peptides Legal? | What Is a COA? | How to Store Research Peptides
For laboratory research use only. Not for human consumption. Not evaluated by the FDA.
